Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals
This evidence builds on what has been learned from randomized controlled trials from the pandemic era to inform clinical practices. Remdesivir was associated with significant reduction in mortality for hospitalized patients including the elderly and those with COVID-19 pneumonia.
Authors
- Paul E. Sax (ORCID: https://orcid.org/0000-0001-8434-174X)
- Yohei Doi (ORCID: https://orcid.org/0000-0002-9620-2525)
- Martin Kolditz (ORCID: https://orcid.org/0000-0001-6022-6827)
- Alpesh Amin (ORCID: https://orcid.org/0000-0002-9790-0245)
- Neera Ahuja (ORCID: https://orcid.org/0000-0002-2979-7530)
- Essy Mozaffari
- Roman Casciano (ORCID: https://orcid.org/0000-0002-7083-9536)
- Paul Loubet (ORCID: https://orcid.org/0000-0002-1218-9432)
- Aastha Chandak (ORCID: https://orcid.org/0000-0001-5653-435X)
- Veronika Müller (ORCID: https://orcid.org/0000-0002-1398-3187)
- Mark Berry (ORCID: https://orcid.org/0000-0002-8534-2012)
Institutions
- Semmelweis University (HU)
- Brigham and Women's Hospital (US)
- Fujita Health University (JP)
- University of Pittsburgh (US)
- University of California, Irvine (US)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Irvine University (US)
- Gilead Sciences (United States) (US)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
- Stanford University (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1093/cid/ciae512
- Citations
- 11
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.28